Evaluating AFT Pharmaceuticals as a potential stock purchase involves analyzing its consistent revenue growth, expanding international footprint across Australasia, Southeast Asia, and the UK, and progress toward its long-term financial targets. Institutional research coverage highlights its strong portfolio of proprietary and over-the-counter brands alongside innovative delivery technologies like intravenous products. However, investors must weigh these growth catalysts against potential R&D costs, foreign exchange risks, and broader market volatility before committing capital.